• 2020

    Dec, 2020 Completion of HelixPOC fully automated microfluidic PCR all-in-one system.

    Oct, 2020 "Robust Performance of Colosafe®!"--Multicenter clinical study published on Clinical Epigenetics

    Sept, 2020 Completion of the round C capital financing of RMB600 million

    Mar, 2020 Acquisition of Helixgen company

    Feb, 2020 CE Marking obtained for Colosafe

  • 2019

    Received CNY 300 million in capital fundraising series B.

    Awarded One Of The Ten Most Advanced In Biomedical Technology of 2018 In China.

    Passed ISO13485:2016 Medical Device Quality Management System certification.

  • 2018

    Approved and licensed by NMPA of China.

    1st place of Guangdong Scientific and Technical Advancement Award in 2018.

    2018 Top 50 of Innovative Biotechnology Enterprises In Guangdong-Hongkong-Macao Greater Bay Area

  • 2017

    COLOSAFE’s registration passed the inspection.

  • 2016

    Product Approval of COLOSAFE.

    Top 50 of The Most Valuable New Investment Enterprises in China.

    2016 China's Top 100 Annual Innovative Growing Enterprises.

    Awarded Excellent Enterprise In The 5th China Innovation and Entrepreneurship Competition.

  • 2015

    Founding of Creative Biosciences and obtained angel round capital fundraising.

  • 2013

    Research team was established at the Sixth Hospital Affiliated to Sun Yat-sen University.

Read more